Global Skin Burns Market Report 2019: Insights, Epidemiology and Market Forecasts 2017-2028 Featuring Pfizer, Avita Medical, Mallinckrodt & RenovaCare
DUBLIN, Feb. 26, 2019 /PRNewswire/ -- The "Skin Burns- Market Insights, Epidemiology and Market Forecast-2028" drug pipelines has been added to ResearchAndMarkets.com's offering.
Skin Burns- Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Skin Burns in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Skin Burns from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
The Skin Burns market report gives a thorough understanding of the Skin Burns by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Skin Burns in the US, Europe, and Japan.
Skin Burns Epidemiology
The incident population of Skin Burns was estimated to be 16,800 [7MM] in 2018. United States accounts for the highest skin-burn cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries UK had the highest incident patient population of Skin Burns, followed France.
Skin Burns Drug Chapters
The treatment regimen of skin burns is mainly classified according to the intensity of the impact and severity of the burn. Moisturizers, over the counter analgesics and /or anti-inflammatory agents, hydration and topical treatments (such as silver releasing agents). Although silver has been used in the form of salts such as Silver nitrate and silver sulfadiazine (Silvadene; King Pharmaceuticals, Inc.) since the past forty years, the available delivery systems often in the form of a salt have been limiting factors to successful biologic use of this noble metal in burn wound care.
Xenografts introduce exogenous collagen into the wound, which aids dermal regeneration. Some of the commonly used products include Matriderm (Suwelack Skin and Health Care Ag) and Oasis (Healthpoint, Fort Worth). Second degree burns are treated with topical medications in superficial cases. However, for deep burn cases TransCyte (Advanced BioHealing, Inc.) is a dressing that is in use. The primary reason being that they impair fibroblast and epithelial proliferation, which in turn delays healing.
Detailed chapters for all of these drugs along with other marketed therapies have been covered in the report.
Skin Burns Market Outlook
The global market of Skin Burns was estimated to be USD 1452.96 million in 2018. The United States accounts for the largest market size of Skin Burns, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. The most promising candidate which was recently approved by the US FDA is Avita Medical's RECELL System (RECELL Autologous Cell Harvesting Device). It is the first spray-on skin product to win approval for the U.S. market and is expected to transform the way burns are treated worldwide.
The dynamics of Skin Burns market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Key players are working robustly on new therapies with novel mechanism of action, including StrataGraft (Mallinckrodt), CellMist System (RenovaCare).
Key Topics Covered:
1 Key Insights
2 Skin Burns Market Overview at a Glance
2.1 Market Share (%) Distribution of Skin Burns in 2017
2.2 Market Share (%) Distribution of Skin Burns in 2028
3 Disease Background and Overview
3.1 Introduction
3.2 Classification
3.3 Signs and Symptoms
3.4 Pathophysiology
3.5 Mechanism involved in Burn-Induced Microvascular Inflammation
3.6 Diagnosis
3.6.1 American Burn Association Burn Unit Referral Criteria
3.7 Diagnostic Approach to Skin Burns
3.7.1 Japanese Dermatological Association: Wound/Burn Guidelines
4 Epidemiology and Patient Population
4.1 Key Findings
5 7MM Total Prevalent Patient Population of Skin Burns
6 Country Wise-Epidemiology of Skin Burns
7 United States
7.1 Assumptions and Rationale
7.2 Total Incident Cases of Skin Burns in the United States
7.3 Total Hospitalized Visit Cases of Skin Burns in the United States
7.4 Incident Cases of Skin Burns by Severity in the United States
7.5 Incident Cases of Skin Burns by Cause in the United States
7.6 Incident Cases of Skin Burns by Gender in the United States
8 EU5
8.1 Assumptions and Rationale
9 Germany
10 France
11 Italy
12 Spain
13 United Kingdom
14 Japan
15 Treatment of Skin Burns
15.1.1 Emergency Management
15.1.2 Specific Treatment
15.2 WHO Guidelines for Management of Burns
15.2.1 Burn Management in Adults
15.2.2 Burn Management in Children
15.2.3 Depth of burn
15.2.4 Wound Care
15.3 NHS Guidelines on the Initial Assessment & Management of Burn-Injured Patients
15.3.1 Assessment & Management of Imminently Life-Threatening Problems
15.3.2 Assessment of the Burn Wound
15.3.3 Intravenous Fluid Resuscitation
15.3.4 Smoke Inhalation Injury
15.3.5 Burn Wound Management
15.3.6 Analgesia
15.3.7 Referral to a Specialised Burns Service
15.3.8 Transfer to a Specialised Burns Service
15.4 Japanese Dermatological Association: Wound/Burn Guidelines
15.5 Therapeutic Algorithm for Local Burn Wound
16 Unmet Needs
17 Marketed Therapies
17.1 Topical Treatments: Antimicrobials, Antibiotics, and others
17.2 Silvadene: Pfizer
17.3 Skin Substitutes
17.3.1 Temporary Skin Substitutes
17.3.2 Permanent Skin Substitutes
17.4 Spray-On Skin Therapy
17.5 Recell: Avita Medical
18 Emerging Therapies
18.1 Key cross competition- Emerging Therapies
18.2 StrataGraft: Mallinckrodt
18.3 SkinGun (CellMist System): RenovaCare
19 Skin Burns: 7 Major Market Analysis
19.1 Key Findings
19.2 Total Market Size of Skin Burns in 7MM
19.1 7 MM Size of Skin Burns by Therapies
20 Market Outlook by Country
21 The United States: Market Outlook
21.1 United States Market Size
21.1.1 Total Market size of Skin Burns in the United States
21.1.2 Skin Burns Market By therapies
22 EU-5 Countries: Market Outlook
23 Japan: Market Outlook
23.1 Japan: Market Size
23.1.1 Total Market size of Skin Burns in Japan
23.1.2 Skin Burns Market By therapies
24 Market Drivers
25 Market Barriers
26 Appendix
Companies Mentioned
- Pfizer
- Avita Medical
- Mallinckrodt
- RenovaCare
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wx33r2/global_skin_burns?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article